Is This Pharmacy's Turnaround Done?
Eric is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Bulls who backed the struggling pharmacy Rite Aid (NYSE: RAD) last year have been rewarded. This pharmacy's turnaround efforts proved the naysayers wrong. Rite Aid is priced like a profitable company now, although by one metric it's still a major bargain. Now investors wonder whether this pharmacy stock's rally can continue. Drug industry trends and other pharmacies' recent moves could help answer this question.
CVS, (NYSE: CVS) Walgreen, (NYSE: WAG) and Rite Aid can all benefit from health care macro trends. An older population could result in more prescription drug sales. Retail health clinics could serve even more patients, and Accenture just released a report about this topic. The Affordable Care Act could mean more patients visiting physicians, which could also result in more prescription drug sales.
There's also one macro factor that could hurt the pharmacies. Patents on many high profile, expensive drugs have expired in the last few years, and investors often call this situation the patent cliff. The patent cliff explains why the pharmacies have been able to sell more lucrative generic drugs, although it also explains the pharmacies' lackluster overall sales. When the patent cliff ends, the pharmacies' margins could drop.
Store closures and the switch to generic drugs have both meant lower revenue for Rite Aid. Both trends remained prominent in May 2013. Rite Aid reported that it has reduced its store count by 37 over the last year. The pharmacy reported -2.7% pharmacy same store sales growth for May, but it also noted that this figure would have risen 1% without recent generic introductions.
The switch to generics has also limited revenue growth for CVS and Walgreen recently. CVS reported -0.1% sales growth last quarter, and Walgreen's total sales were basically unchanged. Facing two competitors that effectively held the line on sales while new generic drugs appeared, Rite Aid's -9.7% sales growth last quarter doesn't look very attractive. CVS and Walgreen currently trade near their annual highs even with relatively flat recent sales, so other factors do come into play for the pharmacies.
A retail clinic staffed by nurse practitioners can offer basic health care, but Rite Aid offers its store visitors remote access to physicians and specialists as well. The NowClinic website explains that patients can talk to OptumHealth's medical staff online at Rite Aid stores, and the OptumHealth physicians can prescribe medication remotely. OptumHealth is a subsidiary of the major health insurance provider UnitedHealth Group.
Walgreen has also been improving its clinics. Back in April, CBS News' Michelle Castillo reported that Walgreen clinics would offer treatments for chronic conditions as well as additional preventative care services. These expanded services could help Walgreen regain even more of the customers it lost to Rite Aid and CVS last year after it couldn't reach a deal with Express Scripts. Once again, Walgreen reported that more of its customers came back in May 2013. Walgreen also reported 3.8% pharmacy same store sales growth for the month.
One statistic in particular makes the best case for Rite Aid bulls. This pharmacy still hasn't matched the profit margins of its rivals, so its price to sales ratio remains extremely low. Rite Aid currently has a P/S of just 0.11, which is far below Walgreen's P/S of 0.67 and CVS' P/S of 0.59. There's no guarantee that Rite Aid can become as profitable as Walgreen or CVS, but Rite Aid still has lots of room to become more efficient.
Rite Aid may become a smaller and more profitable pharmacy. Even with help from macro factors that could boost future prescription drug sales, Rite Aid's sales still look like they're headed downward. On the other hand, generic drug sales and turnaround initiatives could produce more margin improvements for this pharmacy. This turnaround story doesn't look like it's over, but a company with cheap stock and a rising profit margin can also qualify as a value trap. Rite Aid needs to show better sales trends before it becomes an appealing long term investment.
What's inside Supernova?
If you're an investor looking for big long term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
Eric Novinson owns shares of CVS Caremark. The Motley Fool recommends Accenture, Express Scripts, and UnitedHealth Group. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!